Glaukos (NYSE:GKOS) CEO Thomas William Burns Sells 186,945 Shares of Stock

Glaukos Corporation (NYSE:GKOS) CEO Thomas William Burns sold 186,945 shares of Glaukos stock in a transaction on Friday, January 16th. The stock was sold at an average price of $115.00, for a total transaction of $21,498,675.00. Following the completion of the transaction, the chief executive officer owned 153,775 shares in the company, valued at approximately $17,684,125. The trade was a 54.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Thomas William Burns also recently made the following trade(s):

• On Thursday, January 8th, Thomas William Burns sold 88,055 shares of Glaukos stock. The shares were sold at an average price of $115.00, for a total transaction of $10,126,325.00.

Glaukos Stock Up 2.5%

Shares of NYSE:GKOS opened at $123.19 on Wednesday. The stock has a market capitalization of $7.08 billion, a P/E ratio of -79.99 and a beta of 0.67. The stock’s 50-day moving average price is $108.62 and its 200-day moving average price is $95.74. The company has a current ratio of 5.20, a quick ratio of 4.47 and a debt-to-equity ratio of 0.09. Glaukos Corporation has a 12-month low of $73.16 and a 12-month high of $163.71.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.11. Glaukos had a negative return on equity of 7.52% and a negative net margin of 18.65%.The company had revenue of $133.54 million during the quarter, compared to analysts’ expectations of $122.55 million. During the same period in the prior year, the business posted ($0.28) EPS. Glaukos’s quarterly revenue was up 38.1% compared to the same quarter last year. On average, equities analysts anticipate that Glaukos Corporation will post -1.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on GKOS. JPMorgan Chase & Co. lifted their target price on shares of Glaukos from $110.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday, October 30th. The Goldman Sachs Group reissued a “buy” rating and issued a $138.00 price target on shares of Glaukos in a report on Friday, January 9th. Wells Fargo & Company boosted their price objective on shares of Glaukos from $120.00 to $122.00 and gave the company an “overweight” rating in a research report on Thursday, October 30th. Truist Financial increased their target price on shares of Glaukos from $120.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Glaukos in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $127.92.

Institutional Investors Weigh In On Glaukos

Large investors have recently modified their holdings of the stock. Wellington Management Group LLP raised its stake in Glaukos by 10.4% in the third quarter. Wellington Management Group LLP now owns 3,580,670 shares of the medical instruments supplier’s stock worth $292,004,000 after buying an additional 336,266 shares in the last quarter. Primecap Management Co. CA grew its holdings in shares of Glaukos by 23.3% during the 3rd quarter. Primecap Management Co. CA now owns 2,253,788 shares of the medical instruments supplier’s stock worth $183,796,000 after acquiring an additional 425,790 shares during the period. State Street Corp grew its holdings in shares of Glaukos by 5.3% during the 2nd quarter. State Street Corp now owns 2,090,365 shares of the medical instruments supplier’s stock worth $215,914,000 after acquiring an additional 105,972 shares during the period. Ameriprise Financial Inc. raised its position in shares of Glaukos by 3.5% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,999,252 shares of the medical instruments supplier’s stock worth $206,503,000 after acquiring an additional 68,497 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its stake in shares of Glaukos by 38.5% in the 3rd quarter. Alliancebernstein L.P. now owns 1,733,474 shares of the medical instruments supplier’s stock valued at $141,365,000 after purchasing an additional 481,620 shares during the period. Institutional investors own 99.04% of the company’s stock.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.